Review finds GHK-Cu clinical evidence sparse despite broad preclinical claims

The wire

1. 01A systematic evidence-mapping review in Pharmaceutics graded GHK-Cu studies through 12 August 2026 and found preclinical support for matrix remodeling and angiogenesis but thin clinical data.
2. 02A 13-participant post-CO2-laser study was negative on objective endpoints; an 18-participant split-face eyebrow study reported positive hair outcomes without defining speciation.
3. 03Phase 2 acute-wound trial NCT07437586 is still recruiting with no efficacy results; the authors say registration alone is not evidence of translation.

From the source

GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap

Pharmaceutics · 2026 Aug 27 · Mateescu DM, Gavrilescu DM, Mincioaga RI et al.